Icon

ABILIFY (nda021436)- (2MG,5MG,10MG,15MG,20MG,30MG)

ARIPIPRAZOLE OTSUKA
2MG,5MG,10MG,15MG,20MG,30MG
Yes No
2027-Mar-02 Expired
2021-Dec-12 None
None No
ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I • Adjunctive Treatment of Major Depressive Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s disorder.
17 3 13
Total Other Developers 7
Drugs with Suitability No
2MG ** ** - - 13
5MG ** ** - - 13
10MG ** ** - - 13
15MG ** ** - - 13
20MG ** ** - - 13
30MG ** ** - - 13
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** *-*\*\*, **** ****, *******, *********** *************, *********** ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** ****** ****** ****** ******* ******** ******** *** *********** *** ** ******* ***/***, ***********, *** ****** (**) *****-****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.